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Background Enhanced Supportive Care (ESC) is a fresh
approach to supporting people through cancer treatment. At
its heart is better and earlier access to expertise in managing
the adverse effects of cancer and cancer treatments. ESC is
recognised nationally by NHS England, and received a Quality
in Care (QiC) award (February 2016).
Methods In (2012–2015), The Christie NHS Foundation Trust
(a major cancer centre) piloted ESC across 4 cancer disease
groups (skin, breast, hepatobiliary, upper GI). We provided
appropriate supportive care treatments, at an early stage, for
patients who were starting to develop problems with pain or
symptoms, related to their cancer or cancer treatments. We
also worked with oncologists to improve communication with
primary care teams. In order to facilitate early involvement,
we rebranded and changed the name of our team from ‘pal-
liative care team’ to ‘supportive care team’.
Results A reduction was seen in the relative number of emer-
gency admissions in disease groups where there has been sig-
nificant ESC support. Such reductions were not seen
consistently in those disease groups that did not receive signif-
icant ESC support. This reduction in emergency admissions
suggested a potential £1.38m saving over a three year period.
ESC also demonstrated improved patient and carer experience.
Patients benefitted from being presented information in a
hopeful and positive way. The initiative was warmly welcomed
by colleagues in oncology.
Conclusion The landscape of cancer is changing due to better
treatments. More and more people are living longer with
chronic cancer. In line with emerging research on the benefits
of early palliative/supportive care, ESC demonstrates improved
quality and reduction in overall healthcare costs. The reduc-
tion in emergency admissions may reflect early detection and
management of symptom problems, preventing these from
escalating. The next phase of ESC broadens access to suppor-
tive care through integration with acute oncology and devel-
opment of local ambulatory ESC units.
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Background Insomnia involves difficulty with sleep onset,
maintenance, early morning wakening or non-restorative sleep.
Prevalence is 30%–75% in cancer. Consequences include
fatigue and impaired memory or concentration. It is under-
reported, overlooked and severely impairs quality of life.
Subjective sleep diaries underestimate insomnia. Objective
measurements previously required dedicated sleep laboratories.
Wireless medical technology enables objective sleep measure-
ment in the natural environment.
Aims
. Conduct a feasibility study to examine if a wireless monitor
can measure sleep in cancer.




. Correlate objective device results with subjective reports.
Methods A prospective observational study recruited 10 con-
secutive hospice inpatients (IP) and 20 consecutive community
participants (CP) with cancer. Insomnia Severity Index
recorded subjective sleep pattern. Participants used a wireless
non-contact bedside sleep monitor for 3 nights. Three insom-
nia features were examined (sleep onset, maintenance, early
awakening). A daily sleep diary was completed. Acceptability
questionnaires were completed by patient, nurse and family.
Statistical analysis was undertaken with SPSS version 22.
Results The device successfully recorded sleep patterns in all
30 participants. Inpatients: Mean age was 63 years (range 47–
61). 7/10 were positive for one or more insomnia features.
Delayed sleep onset was most common (7/10). Community
Participants: Mean age was 64 years (range 47–84). 15/20
were positive for one or more insomnia features. Fragmented
sleep was most common. 14/20 recorded over 30 min awake
overnight with more than 2 awakenings. Early morning wak-
ening was not present in either cohort. Poor sleep hygiene
was noted in community participants compared to inpatients.
Correlation between subjective and objective measures was not
significant (IP: p=0.07; CP: p=0.106). Patients, nurses and
family members reported 100% device acceptability.
Conclusions
1. A wireless bedside monitor effectively measures sleep in
cancer.
2. High patient acceptability supports clinical use.
3. Cancer-related insomnia features were common in both
cohorts.
4. Objective measurements correlated poorly with subjective.
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Background Medications used to manage symptoms in patients
with cancer have associated, but poorly understood, harms.
The aim of this study was to explore the temporal relation-
ship between oral morphine equivalent daily dose (MEDD),
oral diazepam equivalent daily dose (DEDD) and the daily
anti-cholinergic load (ACL) with cognitive and gastrointestinal
symptoms, performance status, quality of life and survival in
patients receiving palliative care.
Methods Secondary longitudinal analysis of cancer decedents
(n=235) from a palliative care trial with multiple outcome
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measures. At each time-point MEDD, DEDD and ACL were
calculated. Multilevel modelling was used to investigate
independent associations between MEDD, DEDD and ACL,
and cognitive and gastrointestinal symptoms, quality of life,
performance status and survival.
Results Cognitive and gastrointestinal symptoms, performance
status, and quality of life worsened over time. In the adjusted mul-
tilevel analysis significance remained for worsening performance
status (MEDD, p=0.001; DEDD, p<0.001; ACL p=0.035) and
shorter time to death (MEDD, p<0.001; ACL, p<0.01).
Conclusion Commonly used palliative medications were associ-
ated with deteriorating performance status and shorter time to
death. This analysis highlights the importance of adjusting for
other variables, including other medication when exploring
medication-related harms. An understanding of the risk-benefit
balance of medications is needed to maximise net benefit for
patients. Future work to delineate interactions between classes
of drugs and drug-related harms and to evaluate early assess-
ment and management of side-effects is needed in order to
maximise net benefit.
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Background The Neuberger review made a number recommenda-
tion to improve end of life care, including research into the biol-
ogy of dying. An important aspect of the biology of dying is the
identification of biomarkers of the dying process. Biomarkers have
the potential to assist clinicians in recognising dying, in particular
how to distinguish dying from reversible acute deterioration.
Objectives To critically appraise the existing literature on prog-
nostic biological factors that impact survival in advanced can-
cer patients in the last days, weeks or months of life; to
identify prognostic models for advanced cancer patients, which
could assist clinicians to prognosticate in the last days, weeks
or months of life; and to identify candidate biomarkers of the
dying process that can be measured serially in bodily fluids.
Methods A systematically structured review was conducted
using three electronic databases. A hand search of six peer-
reviewed journals and conference abstracts was also conducted.
Studies reporting biomarkers of dying in cancer patients with
a median survival of £90 days, and post-mortem studies were
included.
Results 30 articles were included. There is grade A evidence
for the following biological factors: serum CRP, WBC count,
lymphopaenia, serum sodium, urea, ALP and hypoalbuminae-
mia. An additional nine prognostic factors were identified
with grade B evidence including: thrombocytopaenia, elevated
vitamin B12, hyperbilirubinaemia, hypocholesterolaemia, ele-
vated AST, ALT, LDH and INR. In the last two weeks of life,
a number of biomarkers have been identified but limitations
exist. No post-mortem studies met the inclusion criteria.
Conclusion The biology of dying is an important area for
future research interest. The evidence base to date is largely
focused on symptoms, signs and prognostic factors. We iden-
tify a number common themes shared amongst advanced can-
cer patients, candidate biomarkers of dying, and areas for
future research including non-invasive research methodologies.
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Background Clinically-assisted hydration (CAH) at the end-of-
life is one of the most contentious issues in medicine, partly
due to the fact that there is no good data to support/refute
its use in this scenario.
Methods The study was a cluster randomised trial (feasibility
study) comparing CAH with oral care in patients with
advanced cancer receiving end-of-life care under palliative care
teams in 12 hospices/hospitals in the UK. The main outcomes
related to the feasibility of conducting a definitive study,
whilst the clinical outcomes included the prevalence of end-of-
life care symptoms (particularly hyperactive delirium), adverse
effects, and overall survival.
Results 200 patients were recruited in 1 year, and all feasibility
criteria were achieved. The prevalence of delirium was similar
in the two groups, although the onset of delirium was delayed
in the CAH group (112 hour versus 58 hour). Similar results
were seen for excess respiratory secretions (”death rattle”).
Median survival was greater in the CAH group (i.e. 5 days
versus 3 days). Thirty-eight percent patients discontinued CAH
due to perceived adverse effects (e.g. localised swelling, respi-
ratory secretions).
Conclusion Interventional trials are possible in patients at the
end-of-life, but the methodology needs to be somewhat
adapted. The results of the feasibility study suggest that CAH
may have a positive influence of end-of-life problems, and
possibly survival. However, a larger/definitive study is required
to confirm these findings. CAH is associated with adverse
effects in some patients, but these may be less than perceived
by palliative care specialists.
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